Evidence map›Paper›PMID 23835684›Full record

Trial reportDiabetes care2013

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.

Sun H Kim, Fahim Abbasi, Cindy Lamendola, Alice Liu, Danit Ariel, Patricia Schaaf, Kaylene Grove, Vanessa Tomasso, Hector Ochoa, Yeheng V Liu and 2 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02930265 (Chinese People's Liberation Army General Hospital), which is not on this map. Cited by 41 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 10 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02930265 naunknown statusnot on this mapstarted 2016, after this paper: background citation

Chinese People's Liberation Army General Hospital

TypeinterventionalSponsorChinese PLA General HospitalRan2016 to 2018Enrolled400ConditionsIschemic CardiomyopathyArmsLiraglutide
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 10 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. European Guidelines for Obesity Management in Adults.Obesity facts · 2015 · on this map
    Guideline
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sun H KimCorresponding author: Sun H. Kim, sunhkim@stanford.edu.
Fahim Abbasi
Cindy Lamendola
Alice Liu
Danit Ariel
Patricia Schaaf
Kaylene Grove
Vanessa Tomasso
Hector Ochoa
Yeheng V Liu
Yii-Der Ida Chen
Gerald Reaven
Stanford University · USCedars-Sinai Medical Center · USUniversity of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALAN R. SALTIEL · 2003 to 2026
$40.4M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
NCATS NIH HHS KL2 TR001083NCATS NIH HHS UL1 TR000124NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK063491
6 · The paper itself

Abstract

objectiveThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insulin resistance, cardiovascular disease (CVD) risk factors, and inflammation in a high-risk population for type 2 diabetes (T2DM) and CVD. RESEARCH DESIGN AND

methodsWe randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks. All subjects were advised to decrease calorie intake by 500 kcal/day. Peripheral insulin resistance was quantified by measuring the steady-state plasma glucose (SSPG) concentration during the insulin suppression test. Traditional CVD risk factors and inflammatory markers also were assessed.

resultsEleven out of 35 individuals (31%) assigned to liraglutide discontinued the study compared with 6 out of 33 (18%) assigned to placebo (P=0.26). Subjects who continued to use liraglutide (n=24) lost twice as much weight as those using placebo (n=27; 6.8 vs. 3.3 kg; P<0.001). Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration. Inflammatory markers did not differ between the two groups, but pulse increased after liraglutide treatment (6.4 vs. -0.9 bpm; P=0.001).

conclusionsThe addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD.

Indexed as

Body WeightCaloric RestrictionDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like Peptide 1HumansHypoglycemic AgentsInsulin ResistanceLiraglutideMaleMiddle AgedObesityOverweightPrediabetic StateTriglyceridesGlucagon-Like Peptide 1Hypoglycemic AgentsLiraglutideTriglycerides

Identifiers

PMID23835684
PMCPMC3781545
OpenAlexW2147091345

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.